Pathogen diversity, immunity, and the fate of infections: lessons learned from Trypanosoma cruzi human-host interactions

The complexity of host-pathogen interactions often leads to distinct clinical outcomes upon infection with different pathogen strains. In this Review, we explore the interactions between the highly diverse Trypanosoma cruzi population and the human host. At least 30% of the 7 million individuals with Chagas disease will develop a severe cardiopathy that is among the deadliest heart diseases known. The diversity of the T cruzi population also creates major hurdles for therapy and vaccine development. We also discuss the ecoepidemiological and geographical distribution of T cruzi strains, their susceptibility to treatment, their antigenic diversity, and their effect on the immune response and on disease outcome. Furthermore, we highlight the importance of understanding the T cruzi host-pathogen relationship for guiding new approaches towards development of therapies and vaccines for Chagas disease, and how the information gained by studying this relationship can inspire solutions for other host-pathogen interactions.

Automated summary

This Review explores the interactions between the highly diverse Trypanosoma cruzi population and the human host, and highlights the importance of this relationship for guiding therapies and vaccines for Chagas disease. The diversity of T cruzi and its impact on the immune response pose significant challenges for treatment and vaccine development.